



Docket No.: 61404-028

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 20277
	:	
Donald J. KERRISH, et al.	:	Confirmation Number: 3590
	:	
Serial No.: 10/765,134	:	Group Art Unit: 1644
	:	
Filed: January 28, 2004	:	Examiner: L.E. Crane
	:	
For: PROCESS FOR PRODUCING WET RIBAVIRIN PELLETS	:	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Information Disclosure Statement
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

08/24/2006 MAHMED1 00000035 500417 10765134
02 FC:1806 180.00 DA

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicant further directs the attention of the Examiner to several applications that relate to ribavirin compositions. These include: U.S. Application Nos. 10/882,358 (Publication No. 2005-0019406); 10/665,728 (Publication No. 2004-0258751) and 10/285,188 (Publication No. 2003/0104050 A1). U.S. Application Nos. 10/882,358 and 10/285,188 are believed to be currently pending. In addition, Applicant has included a copy of the last response submitted by the applicants

in the pending applications (as available on the public PAIR database) to advise the Examiner of the currently pending claims in the respective applications.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 500417.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Daniel Bucca, Ph.D.

Registration No. 42,368

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 DB:ajb
Facsimile: 202.756.8087
Date: August 23, 2006

**Please recognize our Customer No. 20277
as our correspondence address.**



SHEET 1 OF 1

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
61404-020SERIAL NO.
10/765,134APPLICANT
Donald J. KERRISH, et al.FILING DATE
January 28, 2004GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	US			
	A1	US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation
		WO2004/026261	Apr. 1, 2004	Three Rivers Pharmaceuticals		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		U.S. Application No. 10/882,358
		Last response submitted by Applicant in U.S. Application No. 10/882,358 as available through the USPTO public PAIR database
		U.S. Application No. 10/665,728
		U.S. Application No. 10/285,188
		Last response submitted by Applicant in U.S. Application No. 10/285,188 as available through the USPTO public PAIR database

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.